At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction

Di Marzo, 2009, The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation, Pharmacol. Res., 60, 77, 10.1016/j.phrs.2009.02.010 Di Marzo, 2008, Targeting the endocannabinoid system: to enhance or reduce?, Nat. Rev. Drug Discov., 7, 438, 10.1038/nrd2553 Jones, 2002, Cardiovascular system effects of marijuana, J. Clin. Pharmacol., 42, 58S, 10.1002/j.1552-4604.2002.tb06004.x Lake, 1997, Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors, J. Pharmacol. Exp. Ther., 281, 1030 Wagner, 1998, Cardiovascular actions of cannabinoids and their generation during shock, J. Mol. Med. (Berl.), 76, 824, 10.1007/s001090050287 Pacher, 2005, Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase, Am. J. Physiol. Heart Circ. Physiol., 289, H533, 10.1152/ajpheart.00107.2005 Malinowska, 2001, Anandamide and methanandamide induce both vanilloid VR1- and cannabinoid CB1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats, Naunyn Schmiedebergs Arch. Pharmacol., 364, 562, 10.1007/s00210-001-0498-6 Zygmunt, 1999, Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide, Nature, 400, 452, 10.1038/22761 Jordt, 2004, Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1, Nature, 427, 260, 10.1038/nature02282 Hiley, 2004, Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling, Biol. Rev. Camb. Philos. Soc., 79, 187, 10.1017/S1464793103006201 Wagner, 2001, Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB1 receptors, Eur. J. Pharmacol., 423, 203, 10.1016/S0014-2999(01)01112-8 Járai, 1999, Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors, Proc. Natl. Acad. Sci. U.S.A., 96, 14136, 10.1073/pnas.96.24.14136 Wang, 2007, Endocannabinoid regulates blood pressure via activation of the transient receptor potential vanilloid type 1 in Wistar rats fed a high-salt diet, J. Pharmacol. Exp. Ther., 321, 763, 10.1124/jpet.106.112904 Domenicali, 2005, Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors, Gut, 54, 522, 10.1136/gut.2004.051599 Ray, 2003, Capsazepine protects against neuronal injury caused by oxygen glucose deprivation by inhibiting Ih, J. Neurosci., 23, 10146, 10.1523/JNEUROSCI.23-31-10146.2003 Ledent, 1999, Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice, Science, 283, 401, 10.1126/science.283.5400.401 Yang, 2007, Role of Ca2+-dependent potassium channels in in vitro anandamide-mediated mesenteric vasorelaxation in rats with biliary cirrhosis, Liver Int., 27, 1045, 10.1111/j.1478-3231.2007.01551.x Járai, 2000, Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice, Hypertension, 35, 679, 10.1161/01.HYP.35.2.679 Awumey, 2008, Cytochrome P-450 metabolites of 2-arachidonoylglycerol play a role in Ca2+-induced relaxation of rat mesenteric arteries, Am. J. Physiol. Heart Circ. Physiol., 294, H2363, 10.1152/ajpheart.01042.2007 O'Sullivan, 2004, Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA), Br. J. Pharmacol., 141, 803, 10.1038/sj.bjp.0705643 Pacher, 2005, Cardiovascular pharmacology of cannabinoids, Handb. Exp. Pharmacol., 168, 599, 10.1007/3-540-26573-2_20 Godlewski, 2010, Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects, Chem. Biol., 17, 1256, 10.1016/j.chembiol.2010.08.013 Milman, 2006, N-Arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties, Proc. Natl. Acad. Sci. U.S.A., 103, 2428, 10.1073/pnas.0510676103 Bradshaw, 2009, The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways, BMC Biochem., 10, 14, 10.1186/1471-2091-10-14 Parmar, 2010, N-Arachidonoyl glycine, an endogenous lipid that acts as a vasorelaxant via nitric oxide and large conductance calcium-activated potassium channels, Br. J. Pharmacol., 160, 594, 10.1111/j.1476-5381.2009.00622.x Poblete, 2005, Anandamide elicits an acute release of nitric oxide through endothelial TRPV1 receptor activation in the rat arterial mesenteric bed, J. Physiol., 568, 539, 10.1113/jphysiol.2005.094292 McHugh, 2010, N-Arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor, BMC Neurosci., 11, 44, 10.1186/1471-2202-11-44 Ho, 2008, ‘Entourage’ effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors, Br. J. Pharmacol., 155, 837, 10.1038/bjp.2008.324 Wheal, 2012, Hydrogen peroxide as a mediator of vasorelaxation evoked by N-oleoylethanolamine and anandamide in rat small mesenteric arteries, Eur. J. Pharmacol., 674, 384, 10.1016/j.ejphar.2011.11.033 Hiley, 2007, GPR55 and the vascular receptors for cannabinoids, Br. J. Pharmacol., 152, 559, 10.1038/sj.bjp.0707421 Johns, 2007, The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects, Br. J. Pharmacol., 152, 825, 10.1038/sj.bjp.0707419 Pacher, 2004, Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice, J. Physiol., 558, 647, 10.1113/jphysiol.2004.064824 Bátkai, 2007, Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury, FASEB J., 21, 1788, 10.1096/fj.06-7451com Mukhopadhyay, 2007, Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity, J. Am. Coll. Cardiol., 50, 528, 10.1016/j.jacc.2007.03.057 Lépicier, 2003, Endocannabinoids protect the rat isolated heart against ischaemia, Br. J. Pharmacol., 139, 805, 10.1038/sj.bjp.0705313 Lo Verme, 2005, The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide, Mol. Pharmacol., 67, 15, 10.1124/mol.104.006353 Di Marzo, 2001, Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells, Biochem. J., 358, 249, 10.1042/0264-6021:3580249 Lagneux, 2001, Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide, Br. J. Pharmacol., 132, 793, 10.1038/sj.bjp.0703902 Joyeux, 2002, Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts, Cardiovasc. Res., 55, 619, 10.1016/S0008-6363(02)00268-7 Montecucco, 2009, CB2 cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion, J. Mol. Cell Cardiol., 46, 612, 10.1016/j.yjmcc.2008.12.014 Defer, 2009, The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy, FASEB J., 23, 2120, 10.1096/fj.09-129478 Rajesh, 2007, Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption, Am. J. Physiol. Heart Circ. Physiol., 293, H610, 10.1152/ajpheart.00236.2007 Rajesh, 2010, Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy, J. Am. Coll. Cardiol., 56, 2115, 10.1016/j.jacc.2010.07.033 Durst, 2007, Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury, Am. J. Physiol. Heart Circ. Physiol., 293, H3602, 10.1152/ajpheart.00098.2007 Bisogno, 2001, Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide, Br. J. Pharmacol., 134, 845, 10.1038/sj.bjp.0704327 Montecucco, 2010, Single administration of the CXC chemokine-binding protein Evasin-3 during ischemia prevents myocardial reperfusion injury in mice, Arterioscler. Thromb. Vasc. Biol., 30, 1371, 10.1161/ATVBAHA.110.206011 Walsh, 2010, Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion, Br. J. Pharmacol., 160, 1234, 10.1111/j.1476-5381.2010.00755.x Amorós, 2010, Endocannabinoids and cannabinoid analogues block human cardiac Kv4.3 channels in a receptor-independent manner, J. Mol. Cell Cardiol., 48, 201, 10.1016/j.yjmcc.2009.07.011 Korantzopoulos, 2008, Atrial fibrillation and marijuana smoking, Int. J. Clin. Pract., 62, 308, 10.1111/j.1742-1241.2007.01505.x Singal, 1998, Doxorubicin-induced cardiomyopathy, N. Engl. J. Med., 339, 900, 10.1056/NEJM199809243391307 Zhang, 2009, Cardiomyocyte death in doxorubicin-induced cardiotoxicity, Arch. Immunol. Ther. Exp. (Warsz), 57, 435, 10.1007/s00005-009-0051-8 Hydock, 2009, Anandamide preserves cardiac function and geometry in an acute doxorubicin cardiotoxicity rat model, J. Cardiovasc. Pharmacol. Ther., 14, 59, 10.1177/1074248408329449 Mukhopadhyay, 2011, Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury, Free Radic. Biol. Med., 50, 179, 10.1016/j.freeradbiomed.2010.11.002 Mukhopadhyay, 2010, CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes, Cardiovasc. Res., 85, 773, 10.1093/cvr/cvp369 Theocharidou, 2012, Cardiac dysfunction in cirrhosis - does adrenal function play a role? A hypothesis, Liver Int., 10.1111/j.1478-3231.2011.02751.x Bátkai, 2001, Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis, Nat. Med., 7, 827, 10.1038/89953 Bátkai, 2007, Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats, Am. J. Physiol. Heart Circ. Physiol., 293, H1689, 10.1152/ajpheart.00538.2007 Pacher, 2005, Cirrhotic cardiomyopathy: an endocannabinoid connection?, Br. J. Pharmacol., 146, 313, 10.1038/sj.bjp.0706332 Yang, 2010, Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids, J. Hepatol., 53, 298, 10.1016/j.jhep.2010.03.011 Guimond, 2007, Quantitative ultrasonic tissue characterization as a new tool for continuous monitoring of chronic liver remodelling in mice, Liver Int., 27, 854, 10.1111/j.1478-3231.2007.01493.x Moezi, 2006, Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB1 and VR1 receptors, Br. J. Pharmacol., 149, 898, 10.1038/sj.bjp.0706928 Pi-Sunyer, 2006, Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial, J. Am. Med. Assoc., 295, 761, 10.1001/jama.295.7.761 Van Gaal, 2005, Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study, Lancet, 365, 1389, 10.1016/S0140-6736(05)66374-X Nissen, 2008, Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial, J. Am. Med. Assoc., 299, 1547, 10.1001/jama.299.13.1547 Di Marzo, 2009, CB1 antagonists for obesity – what lessons have we learned from rimonabant?, Nat. Rev. Endocrinol., 5, 633, 10.1038/nrendo.2009.197 Quarta, 2011, Energy balance regulation by endocannabinoids at central and peripheral levels, Trends Mol. Med., 17, 518, 10.1016/j.molmed.2011.05.002 Di Marzo, 2011, Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes, Handb. Exp. Pharmacol., 203, 75, 10.1007/978-3-642-17214-4_4 Montecucco, 2009, Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis, Atherosclerosis, 205, 433, 10.1016/j.atherosclerosis.2008.12.040 Dol-Gleizes, 2009, Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice, Arterioscler. Thromb. Vasc. Biol., 29, 12, 10.1161/ATVBAHA.108.168757 Tiyerili, 2010, CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function, Basic Res. Cardiol., 105, 465, 10.1007/s00395-010-0090-7 Di Marzo, 2009, Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors, Diabetologia, 52, 213, 10.1007/s00125-008-1178-6 Quercioli, 2011, Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity, Eur. Heart J., 32, 1369, 10.1093/eurheartj/ehr029 Sugamura, 2009, Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages, Circulation, 119, 28, 10.1161/CIRCULATIONAHA.108.811992 Liu, 2000, Functional CB1 cannabinoid receptors in human vascular endothelial cells, Biochem. J., 346, 835, 10.1042/0264-6021:3460835 Rajesh, 2010, Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells, Br. J. Pharmacol., 160, 688, 10.1111/j.1476-5381.2010.00712.x Han, 2009, CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages, Cardiovasc. Res., 84, 378, 10.1093/cvr/cvp240 Rajesh, 2008, Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation, Biochem. Biophys. Res. Commun., 377, 1248, 10.1016/j.bbrc.2008.10.159 Curcio, 2011, Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy, Circ. J., 75, 1287, 10.1253/circj.CJ-11-0366 El-Remessy, 2011, Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line, Diabetologia, 54, 1567, 10.1007/s00125-011-2061-4 Rajesh, 2012, Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy, Diabetes, 61, 716, 10.2337/db11-0477 Horváth, 2012, The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications, Am. J. Pathol., 180, 432, 10.1016/j.ajpath.2011.11.003 Maeda, 2009, Increased serum anandamide level at ruptured plaque site in patients with acute myocardial infarction, Fundam. Clin. Pharmacol., 23, 351, 10.1111/j.1472-8206.2009.00679.x Montecucco, 2008, CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways, Am. J. Physiol. Heart Circ. Physiol., 294, H1145, 10.1152/ajpheart.01328.2007 Rajesh, 2007, CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion, Am. J. Physiol. Heart Circ. Physiol., 293, H2210, 10.1152/ajpheart.00688.2007 Hoyer, 2011, Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo, J. Mol. Cell Cardiol., 51, 1007, 10.1016/j.yjmcc.2011.08.008 Steffens, 2005, Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice, Nature, 434, 782, 10.1038/nature03389 Netherland, 2010, Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice, Atherosclerosis, 213, 102, 10.1016/j.atherosclerosis.2010.07.060 Delsing, 2011, Cannabinoid receptor 2 deficiency in haematopoietic cells aggravates early atherosclerosis in LDL receptor deficient mice, Open Cardiovasc. Med. J., 5, 15, 10.2174/1874192401105010015 Rajesh, 2008, CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration, Br. J. Pharmacol., 153, 347, 10.1038/sj.bjp.0707569 Molica, 2012, The cannabinoid receptor CB2 protects against balloon-induced neointima formation, Am. J. Physiol. Heart Circ. Physiol., 312, H1064, 10.1152/ajpheart.00444.2011 Montecucco, 2011, The activation of the cannabinoid receptor type 2 (CB2) reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques, Eur. Heart J.